At IAG, we leverage our core expertise in medical image analysis and trial design. We work closely with biotech and pharma companies to understand the specifics of their therapeutic agents, so that we can deploy optimal study-specific image analysis and scoring methodologies.
Medical Imaging based biomarkers play critical role in early understanding of therapeutic efficacy and patients’ response to treatment. The choice of MRI, CT, PET or more complex imaging modalities should be specific to the Mechanism of Action, new treatment manifestations, the timing of the imaging visits and study desired outcomes.
When chosen smartly, imaging endpoints can greatly support trial enrichment through patient stratification, provide information of early efficacy and safety, allow to make go/no-go decisions objectively and often predict drug responses at much earlier timepoint.
When it comes to the assessment of efficacy of the drug combinations and development of advanced therapies, the imaging allows reliably and non-invasively monitor short-, mid- and long-term therapeutic outcomes.
Which imaging biomarker to use in your trial will depend on which questions need to be answered. Read more about particular therapeutic areas and the relevant biomarkers.
In early drug development phases, we tend to use more advanced imaging (MRI, PET, multi-modality imaging) to answer specific questions around whether a new drug candidate reaches the target and, if so, in sufficient quantity or whether the expected mechanism of action can be observed.
We deploy a number of our proprietary and state-of-the art methodologies, including those based on AI and Machine Learning. When planning a trial, one must make critical choices on how to use imaging and link imaging and clinical outcomes.
IAG’s expert team supports the use of state-of-the-art and advanced quantitative image reading as well as the deployment of radiomics and multi-omics strategies.
IAG’s platform DYNAMIKA and experienced project management team allow to execute trials with complex designs and advanced endpoints.
Our goal is to accelerate drug development, de-risk trial execution and to ensure integrity and scientific credibility of your data.